Major drugmakers turn to China for licensing deals

Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-developed medicines.Chinese biotechs often retain domestic rights and license t…